According to the Centers for Disease Control and Prevention (CDC), about 50,000 people get infected with HIV each year in the United States. However, 1 in 6 people living with HIV don’t know that they are infected. National HIV Testing Day is observed each year on June 27 to highlight the importance of HIV testing.

CDC recommends that everyone between the ages of 13 and 64 get tested for HIV at least once as part of their routine health care. Regardless of age, people at high risk of HIV should get tested more often.

Visit the AIDSinfo National HIV Testing Day webpage [en español] to learn more about HIV testing and to find a testing center near you.
"On June 5, 2014, FDA approved changes to the Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) fixed-dose combination tablet labeling to include rilpivirine dose adjustment information when Complera is coadministered with rifabutin."

The updated labeling for Complera is available at the FDA website.

More information is available:
"On June 2, 2014, FDA approved a new dosage form, Reyataz (atazanavir) oral powder for use in combination with other antiretroviral agents for the treatment of HIV-1, in patients over 3 months of age and between 10 kg to < 25 kg. The first part of this announcement summarizes the changes relevant to the oral formulation and use in pediatric patients. The second part summarizes other general changes to the label."

The updated labeling for atazanavir is available at the FDA website.

More information is available:
The National Library of Medicine (NLM) is pleased to announce the solicitation of quotations from organizations and libraries to design and conduct projects that will improve access to HIV/AIDS-related health information for patients, the affected community, and their caregivers.

Projects must involve one or more of the following information access categories:

  • Information retrieval; 
  • Skills development; 
  • Resource development; and/or 
  • Equipment acquisition.
Emphasis is placed upon the following types of organizations or arrangements for developing these programs:

  • Community-based organizations (CBOs) or patient advocacy groups currently providing HIV/AIDS-related services to the affected community; 
  • Public libraries serving communities in the provision of HIV/AIDS-related information and resources;
  • Health departments or other local, municipal, or state agencies working to improve public health;
  • Faith-based organizations currently providing HIV/AIDS-related services; and/or 
  • Multi-type consortia of the above-listed organizations that may be in existence or formed specifically for this project.
Awards are offered for up to $40,000.

Quotations are due to NLM on Friday, July 11, 2014.

View the solicitation for the 2014 HIV/AIDS Community Information Outreach Projects on the Federal Business Opportunities website. Small businesses can apply to a specific set-aside.

Please Note: Refer to the Federal Business Opportunities website for notices, updates, and modifications to the HIV/AIDS Community Information Outreach Project 2014 request for quotations (RFQ).
On June 8, AIDSinfo joins the nation in observing Caribbean-American HIV/AIDS Awareness Day. This day serves to raise awareness of HIV/AIDS in the Caribbean, a region disproportionately affected by this disease. According to the U.S Agency for International Development (USAID), outside of sub-Saharan Africa, the Caribbean region has the highest HIV prevalence in the world. In addition to raising awareness, the purpose of this day is to provide information and resources about HIV/AIDS to Caribbean Americans.

Explore our Caribbean-American HIV/AIDS Awareness Day webpage [en español] to learn more about the observance and to find information about HIV/AIDS in this region of the world.
News from NIAID

June 2, 2014: Scientists Uncover Features of Antibody-Producing Cells in People Infected with HIV

"By analyzing the blood of almost 100 treated and untreated HIV-infected volunteers, a team of scientists has identified previously unknown characteristics of B cells in the context of HIV infection. B cells are the immune system cells that make antibodies to HIV and other pathogens. The findings augment the current understanding of how HIV disease develops and have implications for the timing of treatment."
News from FDA
"On June 17, 2014, The Forum for Collaborative HIV Research will host an all-day workshop in Washington, DC at the Kaiser Family Foundation's Barbara Jordan Conference Center as part of an ongoing, open process to seek input from the broader HIV community on specific regulatory issues in cure research - such as acceptable risk, ethics, informed consent and appropriate populations.

"The workshop is a collaboration between The Forum, NIH, and FDA, and will involve community, industry and academia."
AIDSinfo recently updated the AIDSinfo and infoSIDA websites, and they are now automatically optimized for display across all devices—desktop computers, tablets, and smartphones. Visitors to the AIDSinfo and infoSIDA websites will now be able to access all of the website content on any device they are using.

We decided to create a responsive design website—a site that automatically adjusts to any device—because of a shift in ways people are accessing the Internet. Between 2010 and 2014, mobile traffic to the AIDSinfo website increased 10-fold, and almost 90% of health care providers surveyed on the AIDSinfo website have Internet access at the point of care (i.e., while caring for patients), and of those, more than 2/3 use a mobile device when seeing patients. With this redesign, health care providers, researchers, people with HIV/AIDS, their family and friends, and anyone who visits the website will now be able to access the HIV/AIDS medical practice guidelines, drug database, fact sheets, clinical trials search, HIV/AIDS glossary, and all of the other website features in an easy-to-navigate format no matter what device they are using.

If you have saved the mobile site URLs ( and as a Bookmark or Favorite on your tablet or smartphone, there is no need to worry! These URLs will be automatically forwarded to the responsive design website.

We would love to hear from you! Please send your questions or feedback about the responsive design website to [email protected]
New guidelines developed by CDC in partnership with other federal health agencies, public health experts, and community leaders update recommendations on the use of pre-exposure prophylaxis (PrEP) for the prevention of HIV infection in adults in the United States. The guidelines recommend that health care providers consider PrEP for people who are at substantial risk for HIV infection.

The new guidelines include recommended indications for PrEP use; information on Truvada (emtricitabine/tenofovir disoproxil fumarate), the FDA-approved drug for use as PrEP in combination with safer sex practices; and advice for providers on how to support medication adherence.

More information is available:

• CDC: Press release
• CDC: PrEP webpage
• AIDSinfo: Truvada patient fact sheet
News from CDC

May 21, 2014: New CDC Campaign Inspires Life-Saving Conversations About HIV

“The Centers for Disease Control and Prevention today launched Start Talking. Stop HIV., a new national communication campaign encouraging gay and bisexual men to talk openly with their sexual partners about HIV risk and prevention strategies.”

News from NIH

May 19, 2014: 2014 Avant-Garde Awards Focus on Strengthening the Immune System

“With proposals ranging from enhancing the immune system’s ability to fight HIV infection to improving long-term immune health in HIV-infected drug users, three scientists have been chosen to receive the 2014 Avant-Garde Award for HIV/AIDS Research from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health.” 

News from FDA

May 12, 2014: Tivicay (Dolutegravir) Labeling Update

“On May 12, 2014, FDA approved updates to the TIVICAY (dolutegravir) product labeling with information regarding the effect of dolutegravir on renal transporters and drug-drug interaction data between dolutegravir and calcium carbonate or ferrous fumarate.”

View the AIDSinfo patient fact sheet on dolutegravir.
“On May 1, 2014, FDA approved changes to the Edurant (rilpivirine) label to include drug-drug interaction with rilpivirine and metformin and rilpivirine and rifabutin.

“Under section 2 Dosage and Administration:
Rifabutin Co-administration: For patients concomitantly receiving rifabutin, the EDURANT dose should be increased to 50 mg (two tablets of 25 mg each) once daily, taken with a meal.  When rifabutin co-administration is stopped, the EDURANT dose should be decreased to 25 mg once daily, taken with a meal.

“Rilpivirine did not have a clinically significant effect on the pharmacokinetics of metformin.”

The revised label is available at the FDA website.

More information is available:


  • Categories:

    • Locations: